bispecific CS1-BCMA CAR-T
/ Wuhan Sian Medical Tech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 18, 2023
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
(PubMed, Leukemia)
- P1 | "Lenalidomide maintenance after CAR-T infusion and the resistance mechanism of sEMD were preliminarily explored in three patients. CS1-BCMA CAR-T cells were clinically active with good safety profiles in patients with RRMM. Clinical trial registration: This study was registered on ClinicalTrials.gov, number NCT04662099."
CAR T-Cell Therapy • IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Inflammation • Leukopenia • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia
1 to 1
Of
1
Go to page
1